secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001576280-24-000189
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q2 revenue up 29% to $177.2M, raises FY2024 guidance; FDA approves Shield CRC test
--------------------------------------------------------------------------------

- Revenue $177.2M (+29% YoY); precision oncology revenue $166.5M (+33%).
- GAAP net loss $102.6M ($0.84/share); non-GAAP net loss $58.5M ($0.48 loss).
- FY2024 revenue guidance raised to $690-700M (prior $675-685M), growth 22-24%.
- Shield blood test received FDA approval for first-line CRC screening; commercial launch; Medicare covers 45M beneficiaries.
- Clinical tests 49,400 (+14%), biopharma tests 10,475 (+56%); cash $1.0B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628024000189/0001576280-24-000189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628024000189/gh-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001576280-24-000189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer